Fundraising FoxMyosin Therapeutics
Jupiter, US · Founded 2020 · Delaware corporation · 6 known investors
Find your way into Myosin Therapeutics
Sign up to see every warm intro you have to Myosin Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Myosin Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Myosin Therapeutics is a clinical-stage biotechnology company developing a new class of targeted therapies that act on molecular nanomotors such as nonmuscle myosin II to treat cancer and neurological diseases. Its approach targets the physical mechanics of cells driving tumor progression and brain plasticity, with programs including MT-110 and MT-125 for oncology and CNS indications.
Founders & leadership
Myosin Therapeutics was founded in 2020 by Courtney Miller.
Investors · 6
How we know: Florida Opportunity Fund's portfolio page · biospace.com · Not right? Tell us
How we know: biospace.com · Not right? Tell us
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$6M disclosed across 2 rounds · 2022–2025
- $3MSecond Seed FundingMar 2025 · 2 sources
DeepWork Capital (lead), Florida Opportunity Fund (lead), Mint12 Pharma (lead), Dynagrow Capital, Mayo Clinic Ventures, The Sontag Innovation Fund
Source ↗
▶$3MraisedMar 2023 · 4 investors · PharmaceuticalsRule 506(b)
- Patrick Griffin, Ph.D.Director
- Dave AdamsDirector
- Andrew RitterDirector
- Courtney MillerExecutive Officer, Director
- Robert FinizioDirector
- Theodore KameneckaDirector
- Jackson StreeterDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Myosin Therapeutics.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $406.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $325.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Myosin Therapeutics do?
- Myosin Therapeutics is a clinical-stage biotechnology company developing a new class of targeted therapies that act on molecular nanomotors such as nonmuscle myosin II to treat cancer and neurological diseases. Its approach targets the physical mechanics of cells driving tumor progression and brain plasticity, with programs including MT-110 and MT-125 for oncology and CNS indications.
- Who founded Myosin Therapeutics?
- Myosin Therapeutics was founded by Courtney Miller in 2020.
- Who are Myosin Therapeutics's investors?
- Myosin Therapeutics's investors include Florida Opportunity Fund, DeepWork Capital, Mayo Clinic Ventures.
- How much funding has Myosin Therapeutics raised?
- Myosin Therapeutics has disclosed $6M raised across 2 rounds.
- Where is Myosin Therapeutics headquartered?
- Myosin Therapeutics is headquartered in Jupiter, US.